美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · NXTC近 30 天 0 則 · 第 1 / 1 頁
- NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
- Sector Update: Healthcare Stocks Fall Late Afternoon
- Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
- NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
- NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
- NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
- NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
- NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
- NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
- NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
- NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
- NextCure Provides Business Update
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。